Dublin, April 02, 2026 (GLOBE NEWSWIRE) — The “Head and Neck Cancer (HNC) Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The global head and neck cancer (HNC) market is poised for significant growth, with projections indicating an increase from $2.16 billion in 2025 to $2.33 billion in 2026 at a CAGR of 7.8%. By 2030, the market is expected to reach $3.12 billion, fueled by investments in precision oncology, demand for minimally invasive treatments, and advancement in AI-assisted diagnostics.
Growth drivers include a rise in tobacco and alcohol consumption, an increase in HPV-related cancer cases, and a boost in oncology treatment infrastructure. Moreover, enhanced diagnostic technologies and heightened awareness of head and neck cancers are pivotal. The forecast period highlights a trend toward targeted treatments, immunotherapies, and advanced imaging techniques, alongside a shift to early cancer detection and multimodal treatment strategies.
Elevated smoking rates are a significant factor propelling market expansion. Smoking, influenced by stress, societal factors, and marketing, results in severe health risks. Head and neck cancer therapies address tobacco-induced molecular changes, aiming to counteract smoking-related carcinogens and enhance treatment outcomes. A 2024 European Respiratory Society study underscored this by revealing a stark rise in youth smoking rates.
Pharmaceutical companies are increasingly focusing on advanced therapies like immuno-oncology drugs to improve survival rates and address clinical challenges in complex cancers. In November 2024, Dr. Reddy’s Laboratories introduced Toripalimab, an immuno-oncology drug for nasopharyngeal carcinoma, reducing disease progression risk significantly when paired with standard chemotherapy.
Strategic acquisitions, like Coherus BioSciences’ purchase of Surface Oncology Inc., aim to bolster immuno-oncology portfolios. Coherus’ acquisition is set to enhance its market position, integrating promising drug candidates under development for head and neck cancer treatment.
Key industry players include Pfizer Inc., Siemens Healthcare Private Limited, GlaxoSmithKline PLC, Merck KGaA, and AstraZeneca Plc, among others. Geographically, North America leads in market size, while Asia-Pacific is anticipated to experience the fastest growth. Market regions span Asia-Pacific, Western and Eastern Europe, North and South America, and other global sectors.
Why Purchase This Report?
- Obtain a global perspective through an expansive analysis spanning multiple regions and countries.
- Identify growth segments and outperform competitors by leveraging forecast data and emerging trends.
- Understand the broader economic impact and shifts in geopolitical landscapes, trade policies, and regulatory changes.
- Utilize comprehensive market data to benchmark against key competitors and make informed strategic decisions.
- Access updated insights with a detailed Excel data sheet supporting data extraction and easy analysis.
Markets Covered:
- By Type: Laryngeal, Pharyngeal, Salivary Gland, Lip & Oral Cavity, Nasopharyngeal Cancer
- By Treatment: Chemotherapy, Surgery, Radiation Therapy, Targeted Therapy
- By Diagnosis: Bioscopy Screening Tests, Dental Diagnosis, Imaging, Endoscopy
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
- By End User: Hospitals, Specialty Clinics
Companies Mentioned: Major stakeholders such as Pfizer Inc., Siemens Healthcare, F. Hoffmann-La Roche, among others, feature prominently with strategic insights into their market activities.
Geographies Analyzed: Extensive coverage includes regions across Asia-Pacific, Western and Eastern Europe, North America, and beyond.
With a time frame encompassing historical data and forecasts up to 2036, this report is meticulously structured to facilitate strategic decision-making grounded in comprehensive, high-quality market analysis.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $2.33 Billion |
| Forecasted Market Value (USD) by 2030 | $3.12 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
The companies featured in this Head and Neck Cancer (HNC) market report include:
- Pfizer Inc.
- Siemens Healthcare Private Limited
- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- AbbVie Inc.
- Bayer Healthcare AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca Plc
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Koninklijke Philips N.V.
- Boehringer Ingelheim
- Fresenius Kabi AG
- Incyte Corporation
- Exelixis Inc.
- Astellas Pharma Inc.
- Rakuten Medical Inc.
- Merus N.V.
For more information about this report visit https://www.researchandmarkets.com/r/b414kp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Head and Neck Cancer (HNC) Market
